Drugs / Live attenuated HAV vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01865968 Comparator | Oct 2008 → Dec 2011 | hepatitis A virus infection | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live attenuated HAV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01865968 ↗ |
| Known as | Biovac | “A randomized clinical trial of hepatitis A vaccines (1 or 2 doses of inactivated vaccine [Healive] or 1 dose of live attenuated vaccine [Biovac]) was conducted among adults to...” PMID 25969561 ↗ May 2015 |
| Modality | Vaccine | “A randomized clinical trial of hepatitis A vaccines” PMID 25969561 ↗ May 2015 |
| Route | Intramuscular | “Vaccines will be administered with one-dose regimen in the deltoid muscle.” NCT01865968 ↗ |